Penumbra, Inc. (NYSE:PEN) Shares Bought by Employees Retirement System of Texas

Employees Retirement System of Texas raised its position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 31.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,273 shares of the company's stock after purchasing an additional 1,274 shares during the period. Employees Retirement System of Texas' holdings in Penumbra were worth $1,252,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. State Street Corp grew its position in Penumbra by 0.3% during the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company's stock worth $240,298,000 after purchasing an additional 3,863 shares during the period. Baillie Gifford & Co. grew its holdings in shares of Penumbra by 23.4% during the 4th quarter. Baillie Gifford & Co. now owns 730,233 shares of the company's stock worth $173,416,000 after purchasing an additional 138,387 shares during the period. Geode Capital Management LLC lifted its stake in Penumbra by 1.7% during the third quarter. Geode Capital Management LLC now owns 655,572 shares of the company's stock worth $127,417,000 after purchasing an additional 11,257 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Penumbra by 8.2% in the third quarter. Franklin Resources Inc. now owns 319,232 shares of the company's stock valued at $67,473,000 after purchasing an additional 24,091 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in Penumbra by 39.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company's stock valued at $71,831,000 after purchasing an additional 85,284 shares in the last quarter. Institutional investors own 88.88% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PEN shares. Canaccord Genuity Group boosted their price objective on Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Bank of America began coverage on shares of Penumbra in a research note on Friday, March 14th. They set a "buy" rating and a $320.00 price objective for the company. Royal Bank of Canada boosted their price objective on shares of Penumbra from $285.00 to $313.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 19th. StockNews.com downgraded Penumbra from a "buy" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Robert W. Baird upped their price objective on Penumbra from $305.00 to $328.00 and gave the company an "outperform" rating in a research note on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Penumbra presently has a consensus rating of "Moderate Buy" and an average target price of $293.80.

Penumbra Price Performance

Shares of PEN traded up $3.87 during mid-day trading on Friday, reaching $272.44. The stock had a trading volume of 388,806 shares, compared to its average volume of 412,250. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The business has a fifty day moving average of $274.33 and a 200 day moving average of $249.20. The firm has a market cap of $10.54 billion, a price-to-earnings ratio of 801.28, a PEG ratio of 2.83 and a beta of 0.56.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. Equities analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Transactions at Penumbra

In other news, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00. Following the completion of the transaction, the executive vice president now directly owns 66,539 shares in the company, valued at approximately $19,125,304.77. This represents a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Thomas Wilder sold 360 shares of the business's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $266.93, for a total transaction of $96,094.80. Following the completion of the transaction, the director now owns 4,692 shares of the company's stock, valued at approximately $1,252,435.56. This trade represents a 7.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 111,236 shares of company stock worth $31,222,390 over the last quarter. 5.00% of the stock is currently owned by insiders.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.